1. Home
  2. PSNL vs DNA Comparison

PSNL vs DNA Comparison

Compare PSNL & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Personalis Inc.

PSNL

Personalis Inc.

HOLD

Current Price

$7.88

Market Cap

746.8M

Sector

Health Care

ML Signal

HOLD

Logo Ginkgo Bioworks Holdings Inc.

DNA

Ginkgo Bioworks Holdings Inc.

HOLD

Current Price

$9.92

Market Cap

607.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSNL
DNA
Founded
2011
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
746.8M
607.1M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
PSNL
DNA
Price
$7.88
$9.92
Analyst Decision
Strong Buy
Hold
Analyst Count
6
2
Target Price
$11.17
$10.50
AVG Volume (30 Days)
1.4M
1.1M
Earning Date
02-26-2026
02-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$69,103,000.00
$180,606,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$19.41
$3.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.83
$5.00
52 Week High
$11.50
$17.58

Technical Indicators

Market Signals
Indicator
PSNL
DNA
Relative Strength Index (RSI) 40.44 55.80
Support Level $7.27 $7.73
Resistance Level $9.79 $10.23
Average True Range (ATR) 0.86 0.78
MACD -0.28 -0.00
Stochastic Oscillator 14.89 64.69

Price Performance

Historical Comparison
PSNL
DNA

About PSNL Personalis Inc.

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

About DNA Ginkgo Bioworks Holdings Inc.

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Share on Social Networks: